top of page

Philadelphia based Interius BioTherapeutics recently dosed the first patient for its in vivo CAR therapy that edits T and NK cells in the body so they target CD20 positive cells in B-cell malignancies

  • blonca9
  • Nov 25, 2024
  • 1 min read

V.P. of R&D Tim Culp describes the rationale for in vivo CAR programs, what the company will be watching for from a safety standpoint, the development path ahead, and competition.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page